Tech Company Financing Transactions
SpliSense Funding Round
SpliSense, based in Jerusalem, received $13 million from Cystic Fibrosis Foundation and private investors.
Transaction Overview
Company Name
Announced On
6/16/2026
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Undisclosed
Investors
Cystic Fibrosis Foundation (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the continued clinical development of SPL84, its lead inhaled antisense oligonucleotide (ASO) therapy for cystic fibrosis (CF).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Biohouse Labs, Minrav Bldg. 1st Floor, Haddasah Ein Karem
Jerusalem, 9112101
Israel
Jerusalem, 9112101
Israel
Phone
Website
Email Address
Overview
SpliSense is a clinical stage company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of pulmonary diseases. Using an innovative approach, SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and modulate proteins expression and function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gili Hart
Chief Scientific Officer
Batsheva Kerem
VP - Operations
Asaf Cohen
VP - R & D
Efrat Galai
VP - Regulatory Affairs
Lital Friedman
Browse more venture capital transactions:
Prev: 6/16/2026: Respond.io venture capital transaction
Next: 6/16/2026: Foundation Alloy venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs